StocksMedium•12 November 2026•
1 min read
Lineage Cell Therapeutics Misses Revenue Estimates in Q3 2026 Results
Key Facts
1Lineage Cell Therapeutics reported a GAAP EPS of -$0.03, which was in-line with analyst estimates.
2The company's revenue reached $1.43M, missing analyst expectations by $0.56M.
Lineage Cell Therapeutics reported a GAAP EPS of -$0.03 for the third quarter of 2026, which was in-line with analyst estimates. Seeking Alpha reported that the company's revenue reached $1.43M, missing analyst expectations by $0.56M.
LCTX closed at $1.11 on November 11, 2026, ahead of the financial results for the period ending September 2026. The reported revenue represents a 61.1% year-over-year decline according to the company's performance data.